Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

This study presents a valuable finding on the alterations in the autophagic-lysosomal pathway in a Huntington's disease model. The evidence supporting the claims of the authors is solid. However, the ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

These data might lead to a striking change in our view of the role that mTOR inhibition should have in immunosuppressive therapy for allogeneic transplant recipients. You have full access to this ...

He and his colleagues hypothesized that combining paxalisib, a brain-penetrant PI3K/mTOR inhibitor, with RT might improve outcomes in patients with PI3K-mutant brain metastases. The investigators ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron ...

With positive results from a phase III study, ITM Isotope Technologies Munich SE said it has reached a landmark. The clinical trial of ITM-11, a synthetic, targeted radiotherapeutic agent for treating ...

Researchers investigate the sex-dependent microglial response to a colony-stimulating factor 1 receptor (CSF1R) inhibitor.

Patients on the firm's SSTR-targeted radiopharmaceutical had improved progression-free survival compared to patients on an mTor inhibitor in a Phase III trial.